Lipid lowering goals in high risk and very high cardiovascular risk patients: A reasonable challenge?;Objetivos del tratamiento hipolipemiante en pacientes con alto riesgo y muy alto riesgo cardiovascular: ¿Un reto posible?

Revista Clinica Espanola

Volumn 206, Issue 9, 2006, Pages 417-421

  Gomes Belda A ^a   Rodilla, E ^a   Gonzalez C ^a   Costa, J A ^a   Serra, B ^a   Pascual, J M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cardiovascular risk; Combination therapy; LDL c goal; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CREATININE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; EDUCATION PROGRAM; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; METABOLIC SYNDROME X; MOTIVATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 33750436227     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093465     Document Type: Article

References (28)

1. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease: the Framingham study. Ann Intern Med. 1971;74:1-12.
2. Multiple Risk Factor Intervention Trial Research Group. Multiple risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-77.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;334:1383-9.
4. Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
5. The LIPID Study Group. Prevention of cardiovascular events with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
6. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/texCAPS. JAMA. 1998;279:1615-22.
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third Report of the National Cholesterol Education Program in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
10. Cannon CP, Braunwald E, McCabe CH, Radar DJ, Rouleau JL, Balder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
11. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clarck LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-32.
12. Gómez Belda A, Rodilla E, Albert A, García L, González C, Pascual JM. Uso clínico de las estatinas y objetivos terapéuticos en relación con el riesgo cardiovascular. Med Clin (Barc). 2003;121:527-31.
13. García Ruiz FJ, Marín Ibáñez P, Pérez Jiménez F, Pinto X, Nocea G, Ahumada C, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics. 2004;22 Suppl 3:1-12.
14. De la Pena Fernández A, Suárez Fernández C, Cuende Melero I, Muñoz Rodríguez M, Garre Canovas J, Camafort Babkowski M, et al. Grupo estudio CIFARC; Grupo Riesgo Vascular SEMI. Integral control of risk factors in patients of high and very high cardiovascular risk in Spain. CIFARC Project. Med Clin (Barc). 2005; 124(2):44-9.
15. Petrie JC, O'Brien ET, Littler WA, De Swiet M. British Hypertension Society. Recommendations on blood pressure measurement. Br Med J. 1986;293:611-5.
16. Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
18. Plaza Pérez I, Villar Álvarez F, Mata López P, Pérez Jiménez F, Maiques Galán G, Casasnovas Lenguas JA, et al. Control de la colesterolemia en España, 2000: un instrumento para la prevención cardiovascular. Rev Clin Esp. 2000;200:494-515.
19. Maron DJ, Fazio S. Linton MF. Current perspectives on statins. Circulation. 2000;101:207-13.
20. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J. 2005;149:464-73.
21. Kennedy AG, MacLean CH, Litternberg B, Ades PA, Pinckney RG. The Challenge Of Achieving National Cholesterol Goals In Patients With Diabetes. Diabetes Care. 2005;28:1029-34.
22. Rodilla E, García L, Merino C, Costa JA, González C, Pascual JM. Inportancia del síndrome metabólico en el control de la presión arterial y de la dislipemia. Med Clin (Barc). 2004;123:601-5.
23. Foley KA, Simpson RJ, Crouse III, Weiss TW, Markson LE, Alexandre CM. Effectiveness of statins titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003;92:79-81.
24. Massana LI, Plana N. Planificación de la hipercolesterolemia orientada a la obtención de objetivos. Med Clin (Barc). 2005;124:108-10.
25. Pearson TA, Denke MA, McBride PA, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP-ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to satin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80:587-95.
26. Lima J, Fonollosa V, Chacon P. Selective cholesterol absorption inhibition as a new prospect in treatment of hypercholesterolemia. Med Clin (Barc). 2005;125:16-23.
27. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PC, et al. Why don't physicians follow clinical practice guidelines? JAMA. 1999;282:1458-65.
28. Pascual JM, Rodilla E, Sánchez C. Eficacia clínica de la ezemtimiba y objetivos terapéuticos de colesterol LDL. Clin Invest Ateroesclerosis. 2006; 18:57-60.